These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 9678946

  • 1. New tools for biotech product development.
    Quay S.
    Biotechnology (N Y); 1995 Apr; 13(4):319-20. PubMed ID: 9678946
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interferon beta-1b.
    Rudge P.
    Lancet; 1994 Nov 26; 344(8935):1511. PubMed ID: 7968150
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R.
    Clin Neurol Neurosurg; 2002 Jul 26; 104(3):259-64. PubMed ID: 12127665
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Importance of magnetic resonance imaging and gadolinium enhancement.
    Paty DW, Li DK.
    Ann Neurol; 1996 Dec 26; 40(6):951-3. PubMed ID: 9007110
    [No Abstract] [Full Text] [Related]

  • 9. The interferon-beta 1b clinical trial and its implications for other trials.
    Paty DW.
    Ann Neurol; 1994 Dec 26; 36 Suppl():S113-4. PubMed ID: 8017869
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of interferons in demyelinating disease.
    Johnson KP.
    J Neural Transm Suppl; 1997 Dec 26; 49():111-5. PubMed ID: 9266420
    [Abstract] [Full Text] [Related]

  • 12. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM, Racke M, van Den Noort S.
    Arch Neurol; 2000 Jul 26; 57(7):930-2. PubMed ID: 10891973
    [No Abstract] [Full Text] [Related]

  • 13. Serum endothelial adhesion molecules levels correlate with lesion burden in multiple sclerosis patients treated with interferon beta-1b.
    Dinca LP, Lucas M, Zayas MD, Muñoz MA, Garcia Moreno JM, Navarro G, Gata JM, Solano F, Izquierdo G.
    Neurochem Int; 2000 May 26; 36(6):549-53. PubMed ID: 10762092
    [Abstract] [Full Text] [Related]

  • 14. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
    Nervenarzt; 1997 Aug 26; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Multiple sclerosis: new therapeutic concepts or better use of old drugs?
    Clanet M.
    Eur Neurol; 1993 Aug 26; 33(6):401-2. PubMed ID: 8307059
    [No Abstract] [Full Text] [Related]

  • 19. Multiple sclerosis therapy. A practical guide.
    van Oosten BW, Truyen L, Barkhof F, Polman CH.
    Drugs; 1995 Feb 26; 49(2):200-12. PubMed ID: 7729328
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.